JP6370674B2 - タウオパチー治療薬およびそのスクリーニング方法 - Google Patents
タウオパチー治療薬およびそのスクリーニング方法 Download PDFInfo
- Publication number
- JP6370674B2 JP6370674B2 JP2014215409A JP2014215409A JP6370674B2 JP 6370674 B2 JP6370674 B2 JP 6370674B2 JP 2014215409 A JP2014215409 A JP 2014215409A JP 2014215409 A JP2014215409 A JP 2014215409A JP 6370674 B2 JP6370674 B2 JP 6370674B2
- Authority
- JP
- Japan
- Prior art keywords
- drosophila
- tau
- tau protein
- tauopathy
- htau
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000034799 Tauopathies Diseases 0.000 title claims description 42
- 238000000034 method Methods 0.000 title description 33
- 238000012216 screening Methods 0.000 title description 21
- 239000003814 drug Substances 0.000 title description 16
- 229940079593 drug Drugs 0.000 title description 7
- 108010026424 tau Proteins Proteins 0.000 claims description 132
- 102000013498 tau Proteins Human genes 0.000 claims description 131
- 230000004845 protein aggregation Effects 0.000 claims description 65
- 239000003112 inhibitor Substances 0.000 claims description 54
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 claims description 36
- 229930187593 rose bengal Natural products 0.000 claims description 34
- 229940081623 rose bengal Drugs 0.000 claims description 34
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims description 34
- 208000024827 Alzheimer disease Diseases 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 230000000069 prophylactic effect Effects 0.000 claims description 10
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 116
- 150000001875 compounds Chemical class 0.000 description 72
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 51
- 102000057063 human MAPT Human genes 0.000 description 43
- 238000009825 accumulation Methods 0.000 description 31
- 230000007659 motor function Effects 0.000 description 30
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 27
- 229960000907 methylthioninium chloride Drugs 0.000 description 26
- 230000004083 survival effect Effects 0.000 description 24
- 210000002569 neuron Anatomy 0.000 description 22
- 239000001021 fluorone dye Substances 0.000 description 20
- 102000001708 Protein Isoforms Human genes 0.000 description 18
- 108010029485 Protein Isoforms Proteins 0.000 description 18
- 210000005036 nerve Anatomy 0.000 description 16
- 230000009261 transgenic effect Effects 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 14
- 102100039556 Galectin-4 Human genes 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 101150000123 elav gene Proteins 0.000 description 11
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 10
- 241000255588 Tephritidae Species 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 108700009227 Drosophila not Proteins 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000002686 mushroom body Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- -1 alkali metal salt Chemical class 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000007876 drug discovery Methods 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000255925 Diptera Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 3
- 108010001515 Galectin 4 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061296 Motor dysfunction Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000009194 climbing Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108700002304 Drosophila can Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- NMRPBPVERJPACX-UHFFFAOYSA-N octan-3-ol Chemical compound CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 229940016590 sarkosyl Drugs 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000001018 xanthene dye Substances 0.000 description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SDOFMBGMRVAJNF-VANKVMQKSA-N (2s,3s,4s,5r)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)CO SDOFMBGMRVAJNF-VANKVMQKSA-N 0.000 description 1
- KUQNCHZOCSYKOR-UHFFFAOYSA-N 1,1-dioxospiro[2,1$l^{6}-benzoxathiole-3,9'-xanthene]-3',4',5',6'-tetrol Chemical compound O1S(=O)(=O)C2=CC=CC=C2C21C1=CC=C(O)C(O)=C1OC1=C(O)C(O)=CC=C21 KUQNCHZOCSYKOR-UHFFFAOYSA-N 0.000 description 1
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- RUDINRUXCKIXAJ-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptacosafluorotetradecanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RUDINRUXCKIXAJ-UHFFFAOYSA-N 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- NMRPBPVERJPACX-QMMMGPOBSA-N 3-Octanol Natural products CCCCC[C@@H](O)CC NMRPBPVERJPACX-QMMMGPOBSA-N 0.000 description 1
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- BJIZDEKNRFATGL-UHFFFAOYSA-N 9h-xanthen-1-ol Chemical compound O1C2=CC=CC=C2CC2=C1C=CC=C2O BJIZDEKNRFATGL-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102220591064 Cellular tumor antigen p53_S46A_mutation Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101000746263 Conus leopardus Conotoxin Lp5.1 Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150077230 GAL4 gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- DBZJJPROPLPMSN-UHFFFAOYSA-N bromoeosin Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 DBZJJPROPLPMSN-UHFFFAOYSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 102220353736 c.130A>C Human genes 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- REXANTGEEZXBSJ-UHFFFAOYSA-L disodium;4',5'-dibromo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC=C([O-])C(Br)=C1OC1=C(Br)C([O-])=CC=C21 REXANTGEEZXBSJ-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- ZBQZBWKNGDEDOA-UHFFFAOYSA-N eosin B Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC([N+]([O-])=O)=C(O)C(Br)=C1OC1=C2C=C([N+]([O-])=O)C(O)=C1Br ZBQZBWKNGDEDOA-UHFFFAOYSA-N 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- UKZQEOHHLOYJLY-UHFFFAOYSA-M ethyl eosin Chemical compound [K+].CCOC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 UKZQEOHHLOYJLY-UHFFFAOYSA-M 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- FRIPRWYKBIOZJU-UHFFFAOYSA-N fluorone Chemical compound C1=CC=C2OC3=CC(=O)C=CC3=CC2=C1 FRIPRWYKBIOZJU-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- SQFDQLBYJKFDDO-UHFFFAOYSA-K merbromin Chemical compound [Na+].[Na+].C=12C=C(Br)C(=O)C=C2OC=2C([Hg]O)=C([O-])C(Br)=CC=2C=1C1=CC=CC=C1C([O-])=O SQFDQLBYJKFDDO-UHFFFAOYSA-K 0.000 description 1
- 229940008716 mercurochrome Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 108091011150 microtubule binding proteins Proteins 0.000 description 1
- 102000021160 microtubule binding proteins Human genes 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102200145452 rs121908580 Human genes 0.000 description 1
- 102200048773 rs2224391 Human genes 0.000 description 1
- 230000007507 senile plaque formation Effects 0.000 description 1
- 208000022288 senile plaque formation Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B11/00—Diaryl- or thriarylmethane dyes
- C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
- C09B11/06—Hydroxy derivatives of triarylmethanes in which at least one OH group is bound to an aryl nucleus and their ethers or esters
- C09B11/08—Phthaleins; Phenolphthaleins; Fluorescein
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
(1)ヒトタウ発現ショウジョウバエの作製および飼育
ヒトタウタンパク質を複眼特異的に発現する遺伝子組換えショウジョウバエ、ヒトタウタンパク質を神経細胞特異的に発現する遺伝子組換えショウジョウバエ、および、ヒトタウタンパク質を脳キノコ体の神経細胞特異的に発現する遺伝子組換えショウジョウバエを、GAL4−UAS発現系を用いて作製した。ヒトタウ遺伝子(hTau)がGAL4結合エンハンサー配列(UAS)の下流に挿入されたUAS−hTau系統には、yw:UAS−hTau/TM3(未発表、国立長寿医療研究センター創薬モデル動物開発研究プロジェクトチーム、津田玲生プロジェクトリーダーより供与)を用いた。GAL4を複眼特異的に発現するショウジョウバエ系統には、gmr−gal4系統(Hay,BA. et al., Development,120:2121−2129(1994)、国立長寿医療研究センター創薬モデル動物開発研究プロジェクトチーム、津田玲生プロジェクトリーダーより供与)を用いた。GAL4を神経細胞特異的に発現するショウジョウバエ系統には、elavC155−gal4系統(Lin,D.M. et al., Neuron,13:507−523(1994)、国立長寿医療研究センター創薬モデル動物開発研究プロジェクトチーム、津田玲生プロジェクトリーダーより供与)を用いた。GAL4を脳キノコ体の神経細胞特異的に発現するショウジョウバエ系統には、mb247−gal4系統(Schulz,RA. et al., Oncogene,12:1827−1831(1996)、国立長寿医療研究センター創薬モデル動物開発研究プロジェクトチーム、津田玲生プロジェクトリーダーより供与)を用いた。UAS−hTau系統と上記の組織特異的gal4系統をそれぞれ交配し、F1子孫をヒトタウ複眼発現ショウジョウバエ(gmr/Y;hTau/+)、ヒトタウ神経発現ショウジョウバエ(elav/Y;hTau/+)、または、ヒトタウキノコ体神経発現ショウジョウバエ(mb/Y;hTau/+)として得た。
上記(1)の条件にて1ヶ月飼育したショウジョウバエについて、炭酸ガスによる麻酔下において頭部を切断し、氷上にて、約20匹の頭部/1.5mLチューブとなるように回収し、その後、−80℃にて凍結保存した。各チューブに、5μL/頭部のTBS緩衝液(10mMのTris,150mMのNaCl(pH7.4),1mMのEDTA,1mMのEGTA)を添加し、ホモジナイズ後、超遠心し(24,000g、20分、2℃)、上清を別のチューブに回収した。これをサンプルバッファー(120mMのTris(pH6.8),10%の2−メルカプトエタノール,4%のSDS,20%のグリセロール,0.02%のブルモフェノールブルー)と混合して調製したものを、TBS可溶性画分サンプルとした。一方、上清を取り除いた後のペレットに、ショ糖入りのTBS(10mMのTris,800mMのNaCl(pH7.4),1mMのEGTA,10%のスクロース)を添加し、再度ホモジナイズ後、超遠心し(24,000g、20分、2℃)、上清を別の超遠心用チューブに回収した。この上清にサルコシル(終濃度1%(w/v))を加え、室温で3時間インキュベートした。その後、超遠心し(420,000g、1時間、4℃)、上清を除去して得られたペレットにサンプルバッファーを添加して懸濁したものを、サルコシル不溶性画分サンプルとした。タウタンパク質は、凝集していない状態ではTBS可溶性画分に分離され、凝集して不溶化した状態ではサルコシル不溶性画分に分離される。
ショウジョウバエの運動機能は、クライミングアッセイを行い、負の重力走性を評価することにより行った。クライミングアッセイは、以下の条件により行った。ショウジョウバエを餌が入っていない空のバイアルに移し、バイアルを叩いてショウジョウバエを底面に落とした後、ショウジョウバエがバイアルの壁面を登る様子をビデオ撮影した。ショウジョウバエを底面に落としてから10秒後に、バイアルの底から3cmの高さに引かれた線よりも下にいたショウジョウバエを「上に登れなかったハエ」とし、同線よりも上にいたショウジョウバエを「上に登ったハエ」として、それぞれの匹数を数えた。バイアル中のショウジョウバエの総数を100%として、上に登ることができたショウジョウバエの割合を算出した。
上記(1)の条件にてショウジョウバエを飼育し、3日ごとに生存しているショウジョウバエの匹数を数え、生存率を算定した。
ショウジョウバエの記憶試験として、匂いと電気ショックを組み合わせた弁別学習試験を行った。ショウジョウバエの嫌いな2種類の匂い物質(3−オクタノールおよび4−メチルシクロヘキサノール)を用い、いずれか一方の匂い(匂い1)を、電気ショック(60Vのパルス電流/5秒間隔)を与えながら1分間嗅がせた。45秒間の休憩を挟み、次いで、もう一方の匂い(匂い2)を電気ショックを与えずに1分間嗅がせた。これにより、ショウジョウバエは、最初に嗅いだ匂い1を危険な匂いとして学習する。学習の1分30秒後、匂い1を入れた容器と匂い2を入れた容器を同時に与え、ショウジョウバエがどちらの匂いを選択するかを観察した。匂い1を入れた容器と匂い2を入れた容器の間にショウジョウバエを置き、匂い1を入れた容器に移動したショウジョウバエの数と匂い2を入れた容器に移動したショウジョウバエの数とが等しい場合の記憶スコアを0%とし、全てのショウジョウバエが匂い2を入れた容器に移動した場合の記憶スコアを100%として定義した。その後、匂いと電気ショックとの組み合わせを交換して同様の試験を行い、この結果と最初の結果との平均値を求め、これを1回の試験結果とした。
上記(1)で作製したヒトタウ複眼発現ショウジョウバエ(gmr/Y;hTau/+)における凝集タウの蓄積について、上記(2)の手順により定量した。凝集タウの定量は、非投与群とメチレンブルー投与群について行った。両群の凝集タウの蓄積量の比較定量は、非投与群の数値を100%として行った。
次いで、上記(1)で作製したヒトタウ神経発現ショウジョウバエ(elav/Y;hTau/+)について、上記(3)の手順により、運動機能を評価した。さらに、上に登ったハエ群と、上に登れなかったハエ群とを回収し、それぞれの群について、上記(2)の手順により、脳内における凝集タウの蓄積を定量した。両群の凝集タウの蓄積量の比較定量は、上に登れなかったハエ群の数値を100%として行った。
上記3で確立したスクリーニング系を用いて、フルオロン色素であるローズベンガルのタウタンパク質凝集阻害効果を評価した。上記(1)で作製したヒトタウ神経発現ショウジョウバエ(elav/Y;hTau/+)について、ローズベンガル投与群と、非投与群(陰性対照)と、メチレンブルー投与群(陽性対照)とを準備し、上記(2)の手順により、脳内における凝集タウの蓄積を定量した。各群の凝集タウの蓄積量の比較定量は、非投与群の数値を100%として行った。また、上記(3)の手順により、上記各群の運動機能を測定した。
メチレンブルーは、タウ凝集抑制作用を有する一方で、長期間の投与における慢性毒性が懸念されている。そこで、ヒトタウ神経発現ショウジョウバエまたは野生型ショウジョウバエに対しローズベンガルまたはメチレンブルーを投与し、上記(4)の手順により、それぞれの生存率を算定して比較することにより、ローズベンガルの毒性を評価した。対照には、非投与群のショウジョウバエを用いた。
ヒトタウ発現ショウジョウバエにローズベンガルを投与してタウの凝集を阻害した場合に、ショウジョウバエの学習記憶能力に変化が見られるかどうかを、上記(1)で作製したヒトタウキノコ体神経発現ショウジョウバエ(mb/Y;hTau/+)を用いて、上記(5)の手順により試験した。ローズベンガルは、1週間にわたり投与した。また、対照として、野生型ショウジョウバエの非投与群とローズベンガル投与群を作製し、同様に試験した。
Claims (3)
- ローズベンガルまたはその薬学的に許容される塩を含んでなる、タウタンパク質凝集阻害剤。
- 請求項1に記載のタウタンパク質凝集阻害剤を含有する、タウオパチーの治療薬または予防薬。
- 前記タウオパチーがアルツハイマー病である、請求項2に記載の治療薬または予防薬。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014215409A JP6370674B2 (ja) | 2014-10-22 | 2014-10-22 | タウオパチー治療薬およびそのスクリーニング方法 |
US14/919,241 US20160175463A1 (en) | 2014-10-22 | 2015-10-21 | Therapeutic Agent for Tauopathy and Method for Screening Thereof |
US15/655,997 US10478511B2 (en) | 2014-10-22 | 2017-07-21 | Therapeutic agent for tauopathy and method for screening thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014215409A JP6370674B2 (ja) | 2014-10-22 | 2014-10-22 | タウオパチー治療薬およびそのスクリーニング方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018129779A Division JP2019007963A (ja) | 2018-07-09 | 2018-07-09 | タウオパチー治療薬およびそのスクリーニング方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016079160A JP2016079160A (ja) | 2016-05-16 |
JP6370674B2 true JP6370674B2 (ja) | 2018-08-08 |
Family
ID=55957715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014215409A Expired - Fee Related JP6370674B2 (ja) | 2014-10-22 | 2014-10-22 | タウオパチー治療薬およびそのスクリーニング方法 |
Country Status (2)
Country | Link |
---|---|
US (2) | US20160175463A1 (ja) |
JP (1) | JP6370674B2 (ja) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
US20050108779A1 (en) | 2003-10-21 | 2005-05-19 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Italian |
WO2007149293A2 (en) | 2006-06-16 | 2007-12-27 | Envivo Pharmaceutical, Inc. | Transgenic flies expressing tau and amyloid precursor fragment |
CN105920216A (zh) | 2008-05-09 | 2016-09-07 | 西奈山医学院 | 用于预防和治疗神经退行性疾病的方法 |
-
2014
- 2014-10-22 JP JP2014215409A patent/JP6370674B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-21 US US14/919,241 patent/US20160175463A1/en not_active Abandoned
-
2017
- 2017-07-21 US US15/655,997 patent/US10478511B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US10478511B2 (en) | 2019-11-19 |
JP2016079160A (ja) | 2016-05-16 |
US20170319716A1 (en) | 2017-11-09 |
US20160175463A1 (en) | 2016-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fortuna et al. | Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson’s disease-like symptoms in mice | |
Swarnkar et al. | Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease | |
US20160193231A1 (en) | Rett syndrome and treatments therefore | |
Bavley et al. | Rescue of learning and memory deficits in the human nonsyndromic intellectual disability cereblon knock-out mouse model by targeting the AMP-activated protein kinase–mTORC1 translational pathway | |
Sugimoto et al. | Heterozygous mice deficient in Atp1a3 exhibit motor deficits by chronic restraint stress | |
Chegão et al. | Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes | |
US20140242091A1 (en) | Method for treating pathologies associated with hypoxia using mif inhibitors | |
JP2019007963A (ja) | タウオパチー治療薬およびそのスクリーニング方法 | |
JP6370674B2 (ja) | タウオパチー治療薬およびそのスクリーニング方法 | |
JP6688503B2 (ja) | 医薬用組成物 | |
US20210145802A1 (en) | Therapy for ophthalmological conditions | |
JP2019510088A (ja) | Parisのファルネシル化によってパーキンソン病を予防または治療する方法 | |
JP7249433B2 (ja) | 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物 | |
US12059433B2 (en) | Treatment for autistic spectrum disorder (ASD) and relevant symptoms | |
JP2019501972A (ja) | Tdp−43タンパク質症の治療のためのタクロリムス | |
US20160120858A1 (en) | Pharmaceutical composition containing clioquinol for treating autism spectrum disorders | |
WO2020152607A1 (en) | Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration | |
Kim et al. | Levosimendan prevents tau pathology by inhibiting disulfide-linked tau oligomerization posing as a promising anti-tau therapeutics | |
AU2022283770B2 (en) | Cyclic plasmenylethanolamines | |
US20210195875A1 (en) | Non-human animals exhibiting degenerative symptom attributed to protein aggregation | |
Liu et al. | Thidoredxin-2 overexpression fails to rescue chronic high calorie diet induced hippocampal dysfunction | |
US20240115581A1 (en) | Combination therapy for the treatment or prevention of neurological disorders | |
Nixon | The Effects of Cannabinoid Compounds on the Brain and Behaviour of Mouse Models of Alzheimer’s Disease | |
Omer | Characterizing Rare Disease-Causing Mutations in Genes Affecting Cation-Coupled Chloride Cotransport | |
Li | PGC-1α in neurodegeneration and ageing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170804 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180606 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180619 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180711 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6370674 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |